National Bank of Canada FI Purchases 150,897 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

National Bank of Canada FI raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 72.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 359,965 shares of the medical equipment provider’s stock after acquiring an additional 150,897 shares during the quarter. National Bank of Canada FI owned approximately 0.10% of Intuitive Surgical worth $119,091,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. WCM Investment Management LLC purchased a new position in Intuitive Surgical during the 4th quarter worth approximately $575,536,000. International Assets Investment Management LLC increased its holdings in Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after buying an additional 684,749 shares in the last quarter. Alphinity Investment Management Pty Ltd raised its holdings in Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after purchasing an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Intuitive Surgical in the third quarter valued at approximately $178,667,000. Finally, Quadrature Capital Ltd raised its stake in shares of Intuitive Surgical by 466.2% during the 3rd quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after buying an additional 280,480 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 1.0 %

ISRG stock traded up $3.71 during mid-day trading on Friday, hitting $381.36. 1,028,858 shares of the company were exchanged, compared to its average volume of 1,492,254. The business has a fifty day simple moving average of $385.40 and a 200-day simple moving average of $350.34. The firm has a market capitalization of $135.27 billion, a P/E ratio of 68.84, a PEG ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the firm earned $1.00 EPS. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. Research analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Activity

In related news, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 226,928 shares of company stock valued at $87,833,828. 0.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Piper Sandler increased their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Barclays raised their price objective on Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Truist Financial increased their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Finally, Citigroup boosted their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.